Phase IIa clinical trial of histone-H1-3 [OncoHist] for the treatment of refractory and relapsed acute myeloid leukaemia and an additional undisclosed orphan cancer indication.

Trial Profile

Phase IIa clinical trial of histone-H1-3 [OncoHist] for the treatment of refractory and relapsed acute myeloid leukaemia and an additional undisclosed orphan cancer indication.

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Histone H1-3 (Primary)
  • Indications Acute myeloid leukaemia; Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top